Financial accumulation and technological dominance by transnational biopharmaceutical companies-and its global consequences-have been an important research topic at innovation economics,institutional economics,and int...Financial accumulation and technological dominance by transnational biopharmaceutical companies-and its global consequences-have been an important research topic at innovation economics,institutional economics,and interational political economy literature.The United States is a privileged field for investigation,as it is home both for the companies that control the core of this industry and for the highest State-led investments on biomedical research and development(R&D).New analytical approaches that focus on State-Company interactions identify dysfiunctional relations on risks and rewards.However,a neglected angle on this debate is the geopolitical dynamics surrounding market concentration,knowledge control,and technological asymmetry in the biopharmaceutical sector.This paper combines a qualitative analysis of State-Company institutional complementarities in the biopharmaceutical sector,comprised by analysis of selected official documents,review of empirical data and a case study,with a theoretical investigation inspired on the institutional thought of Torstein Veblen,the structuralism of Susan Strange and the realistic approach to intemnational political economy of Jose Luis Fiori.We propose a new analytical framework in which State-Company interactions in the US are seen as symbiotic,taken under the systemic fiunctioning of a"medical-technological-financial-complex",what suggests"biopharmaceutical geopolitics"as an important feld for future studies.展开更多
文摘Financial accumulation and technological dominance by transnational biopharmaceutical companies-and its global consequences-have been an important research topic at innovation economics,institutional economics,and interational political economy literature.The United States is a privileged field for investigation,as it is home both for the companies that control the core of this industry and for the highest State-led investments on biomedical research and development(R&D).New analytical approaches that focus on State-Company interactions identify dysfiunctional relations on risks and rewards.However,a neglected angle on this debate is the geopolitical dynamics surrounding market concentration,knowledge control,and technological asymmetry in the biopharmaceutical sector.This paper combines a qualitative analysis of State-Company institutional complementarities in the biopharmaceutical sector,comprised by analysis of selected official documents,review of empirical data and a case study,with a theoretical investigation inspired on the institutional thought of Torstein Veblen,the structuralism of Susan Strange and the realistic approach to intemnational political economy of Jose Luis Fiori.We propose a new analytical framework in which State-Company interactions in the US are seen as symbiotic,taken under the systemic fiunctioning of a"medical-technological-financial-complex",what suggests"biopharmaceutical geopolitics"as an important feld for future studies.
